Several studies4–9 from the past few years have attempted to assess the risk of death in cohorts of CF patients based on several baseline characteristics. According to these studies, several factors, in addition to FEV1, have been shown as important predictors. According to the largest studies,,4 using data from the Cystic Fibrosis Registry, pulmonary function, number of exacerbations, age, gender, weight, presence of diabetes, pancreatic insufficiency, and type of bacterial colonization are all important parameters in predicting 5-year survival. Another study7 found similar predictors, but for 2-year survival FEV1 alone performed almost as well. The disadvantages of these studies are the inclusion of all patients with CF, regardless of whether they were transplant candidates or not. Smaller studies,5–6 have assessed only patients listed on the lung transplant list or single-center patients, but they lacked the power to adequately assess many factors. A recent study9used a multicenter approach to identify predictors of death for patients on the waiting list. Lung function, Paco2, and referral from an accredited CF center were all important predictors of outcome. In addition, patients who had been referred in later years had decreased risk of death. The study included adult and pediatric patients in two different countries with different listing systems; therefore, it is difficult to assess how the findings apply in each specific situation. Finally, a recent study10 found that patients with severe exacerbations requiring ICU care have a very poor prognosis.